Celyad (CYAD)
(Delayed Data from NSDQ)
$0.47 USD
0.00 (0.00%)
Updated May 18, 2023 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Celyad SA [CYAD]
Reports for Purchase
Showing records 41 - 56 ( 56 total )
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Blasts get blasted but dose needs definition
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Celyad Presents More CYAD-01 THINK Data in r/r AML Patients at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
CYAD-01 Phase 1 EPITHINK and DEPLETHINK Updates in AML Patients at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Celyad Announces Dosing First mCRC Patient in Phase 1 alloSHRINK Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Highly encouraging data on dose responses
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Celyad Announces 3Q18 Business Update; Phase 1 Data Updates at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
CYAD Presents CYAD-01 Solid Tumor Platform Progress at SITC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Celyad to Present Updated Phase 1 THINK Data for CYAD-01 at ASH 2018; Encouraging AML Data in Abstract
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Celyad Doses First Colorectal Cancer Patient With CYAD-01 Following Preconditioning Chemo
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Reports 1H18 Results; More CYAD-01 Preliminary Data Planned for ASH and SITC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Allogeneic trial approved in colorectal cancer
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Celyad Announces FDA Acceptance of IND for CYAD-101; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Full Speed Ahead With a New CAR (T), Initiating Coverage With a Buy Rating and $45 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Developing a sophisticated clinical strategy
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Progressing a broad clinical strategy
Provider: EDISON INVESTMENT RESEARCH LIMITED